Kazuki Nozawa, Medical Oncologist at Nagoya City University, shared on X:
“The SABCS26 abstract titles are out!
One study that particularly caught my attention is STOP-HER2, which will be presented in GS3.
These results could provide crucial insights into de-escalation strategies for exceptional responders to anti-HER2 therapy.
Looking forward to the data!”
You can also read: Trastuzumab Deruxtecan Secures EU Approval for Residual HER2-Positive Early Breast Cancer Following DESTINY-Breast05 Survival-Free Disease Benefit.
